Skip to content
NeuroTechGuide

FDA clears Cala kIQ Plus, a next-generation wrist stimulator for tremor

The updated wearable adds new therapy modes and adaptive calibration for hand tremor in essential tremor and Parkinson's disease.

In briefRegulationNeuromodulation

The FDA has cleared Cala kIQ Plus, the next generation of Cala Health’s wrist-worn device that treats action hand tremor in essential tremor and Parkinson’s disease with transcutaneous afferent patterned stimulation (TAPS). The new version adds therapy modes and adaptive calibration to personalize treatment. Later in April, Cala also secured $50 million in growth financing from Trinity Capital to expand commercially.

Research published in 2025 linked TAPS to changes in the same thalamic circuits that deep brain stimulation targets (our coverage).

Learn more: Deep brain stimulation · Cala Health

Share:XLinkedInBlueskyEmail

More news